Mohammad Azharuddin

Mohammad Azharuddin

Auto-generated profile, based on publicly available information

Mohammad Azharuddin

Division of Pharmacology, Department of Pharmaceutical Medicine, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2021 in International Journal Of Clinical Practice
Verified
Journal Article
Closed access
PDF file
AZAzharuddin
Azharuddin
MAMohammad Adil
Mohammad Adil
MSManju Sharma
Manju Sharma
Bishal GyawaliBishal Gyawali
Bishal Gyawali

25 November 2019 in Journal of Evidence-Based Medicine
Verified
Journal Article
Closed access
PDF file
AZAzharuddin
Azharuddin
MAMohammad Adil
Mohammad Adil
PGPinaki Ghosh
Pinaki Ghosh
PKPrem Kapur
Prem Kapur
MSManju Sharma
Manju Sharma

1 June 2020 in Osteoporosis and Sarcopenia
Verified
Journal Article
Open access
AZAzharuddin
Azharuddin
MAMohammad Adil
Mohammad Adil
RKRashid Ali Khan
Rashid Ali Khan
PGPinaki Ghosh
Pinaki Ghosh
PKPrem Kapur
Prem Kapur
MSManju Sharma
Manju Sharma
This paper systematically and critically reviewed all published economic evaluations of drugs for the treatment of postmenopausal osteoporosis. A systematic search was conducted using relevant databases for economic evaluations to include all relevant English articles published between January 2008 to January 2020. After extracting the key study characteristics, methods and outcomes, we evaluated each article using the Quality of Health Economic Studies (QHES) and the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) instruments. A total of 49 studies met the inclusion criteria. Majority of studies were funded by the industry and reported favorable cost-effectiveness. Based on the QHES total scores, studies (n = 35) were found to be industry-funded with higher QHES mean 82.44 ± 8.69 as compared with nonindustry funding studies (n = 11) with mean 72.22 ± 17.67. The overall mean QHES scores were found to be higher 79.06 ± 11.84, representing high quality (75–100) compared to CHEERS scores (%) 75.03 ± 11.21. The statistical pairwise comparison between CHEERS mean (75.03 ± 11.21) and QHES mean (79.06 ± 11.84) were not statistically significant (P = 0.10) whereas, QHES score showed higher means as compared to CHEERS. This study suggests the overall quality of the published literatures was relatively few high-quality health economic evaluation demonstrating the cost-effectiveness of drugs for postmenopausal osteoporosis, and the majority of the literature highlights that methodological shortcoming.

1 January 2026 in Health Technology Assessment
Verified
Journal Article
Open access
DBDwayne Boyers
Dwayne Boyers
MCMoira Cruickshank
Moira Cruickshank
MAMohammad Azharuddin
Mohammad Azharuddin
PMPaul Manson
Paul Manson
DSDiane Swallow
Diane Swallow
MBMiriam Brazzelli
Miriam Brazzelli
Background: Chronic tic disorders and Tourette syndrome typically present around age 5, with peak severity between ages 10 and 12. Treatment approaches vary by country and service availability and include psychoeducation, behavioural therapy, pharmacological therapies and deep brain stimulation. Digitally enabled interventions may improve outcomes. Objectives: We evaluate the clinical and cost-effectiveness of two digital technologies, Online Remote Behavioural Treatment for Tics and Neupulse and identify evidence gaps for future research. Methods: We searched major electronic databases (MEDLINE, EMBASE, Cochrane Library, Web of Science, and Cumulative Index to Nursing and Allied Health Literature) for published studies on clinical and cost-effectiveness. Data were extracted, assessed for bias using Cochrane risk-of-bias tool (version 2), and pooled using random-effects meta-analysis where appropriate. Cost-effectiveness was evaluated using a Markov cohort model with five tic severity states based on the Yale Global Tic Severity Scale – Total Tic Severity Score scale, from a United Kingdom National Health Service perspective. Model inputs were obtained from the Online Remote Behavioural Treatment for Tics study, company data, expert opinion and additional literature. Results: We identified three trials reported across 14 publications: 2 comparing Online Remote Behavioural Treatment for Tics with online psychoeducation, and 1 comparing Neupulse with sham stimulation and a waitlist control. All were assessed as low risk of bias. Meta-analysis of the 2 Online Remote Behavioural Treatment for Tics studies (445 participants) showed significantly lower Yale Global Tic Severity Scale – Total Tic Severity Score at 3 and 12 months compared to online psychoeducation. Results of secondary outcomes were mixed. Neupulse showed significantly lower Yale Global Tic Severity Scale – Total Tic Severity Score, and improvements in motor and phonic tic scores at 4 weeks compared to sham, but no differences in Yale Global Tic Severity Scale-Impairment or Premonitory Urge for Tics Scale – Revised scores. A definitive base-case incremental cost-effectiveness ratio could not be determined due to limited long-term data and uncertainty around long-term combinations of effectiveness and intervention costs in United Kingdom National Health Service practice. Probabilistic incremental cost-effectiveness ratios ranged from £642 per quality-adjusted life-year gained to Online Remote Behavioural Treatment for Tics being dominated. The probability of Online Remote Behavioural Treatment for Tics being cost-effective at a threshold value of £20,000 per quality-adjusted life-year ranged from 52% to 89% across a range of scenarios. Cost-effectiveness results for Neupulse were even more uncertain due to a lack of published data, only a 4-week follow-up and uncertainty surrounding the intervention cost. Limitations: Evidence for Online Remote Behavioural Treatment for Tics and Neupulse was limited, with inconsistencies in the outcomes assessed. Comparators did not include face-to-face behavioural therapy and it was not possible to differentiate the effects of online delivery from those of exposure and response prevention. Cost-effectiveness results are uncertain due to a lack of long-term data. Conclusions: Both Online Remote Behavioural Treatment for Tics and Neupulse appear to significantly reduce Yale Global Tic Severity Scale – Total Tic Severity Score, but there were no improvements in the Yale Global Tic Severity Scale-Impairment scores and mixed results across other secondary outcomes, meaning it is unclear to what extent improvements in tic severity scores can translate to improvements in quality of life. Cost-effectiveness estimates were highly uncertain due to a lack of long-term evidence. Future studies: Replication studies are needed to confirm findings. Longer follow-up – particularly for Neupulse – is essential to understand sustained effects and long-term cost-effectiveness. More data on the natural course of tic severity and the sustainability of treatment effects would reduce uncertainty in economic modelling. Future research should also prioritise outcomes that reflect real-life impact on people’s daily functioning. Study registration: This study is registered as PROSPERO CRD42024508045. Funding: This award was funded by the National Institute for Health and Care Research (NIHR) Evidence Synthesis programme (NIHR award ref: NIHR136022) and is published in full in Health Technology Assessment ; Vol. 30, No. 8. See the NIHR Funding and Awards website for further award information.